Jessie George, MD
Nephrology · Plano, TXNPI 1922021179
Payments from drug & device makers
What this record shows
This record is dominated by education: $135 of the $223 with a category attached, or 60.5%. 5 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 50.9% of the total. Reporting peaked in 2020 at $96 and has fallen 85.2% since, to $14 in 2025. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.
Across 7 payments — averaging $31.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$113
- Aurinia Pharma U.S., Inc.$60
- OPKO Pharmaceuticals, LLC$22
- Mannkind Corporation$14
- Vifor Pharma, Inc.$13
What the payments were for
- Food & beverage$8839%
- Education$13561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $113 |
| Aurinia Pharma U.S., Inc. | 2 | $60 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Mannkind Corporation | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
How this compares
$223 in reported general payments places this provider in the 15th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 84 | $81,947 |
| JardianceEmpagliflozin | 38 | $45,044 |
| VeltassaPatiromer Calcium Sorbitex | 36 | $39,200 |
| Sevelamer Carbonate | 52 | $12,768 |
| Nifedipine ErNifedipine | 118 | $6,208 |
| Calcium Acetate | 25 | $4,253 |
| Calcitriol | 205 | $3,352 |
| Valsartan | 66 | $3,172 |
| Potassium Citrate ErPotassium Citrate | 33 | $2,538 |
| Tamsulosin Hcl | 118 | $1,453 |
| Losartan Potassium | 131 | $1,386 |
| Allopurinol | 99 | $1,194 |
| Carvedilol | 146 | $987 |
| Febuxostat | 12 | $936 |
| Furosemide | 177 | $928 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Plano
- Neghae MawlaPlano$229K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.